Doxorubicin (DOX) is a frequently used chemotherapeutic drug for breast cancer, but its site specificity and local internalization into tumor cells is rather low. In this paper we conjugated magnetic nanoparticles (MNPs) with DOX and/or a pseudopeptide NucAnt (N6L) as modality to enhance DOX-induced antitumor effects in breast cancer cells (BT474). In this context, we determined cellular uptake of MNP formulations, analyzed cell viability and expression of apoptotic and cell cycle proteins after magnetic hyperthermia (43°C, 1 h) in vivo and in vitro.
Introduction
Chemotherapeutic drugs play an important role in cancer treatment. Most of them show complex mechanisms of action. One example is the drug Doxorubicin (DOX), an anthracycline antibiotic, which intercalates with DNA , interrupts topoisomerase II activity and induces free radicals resulting in oxidative damage and DNA double-strand breaks [1] , [2] , [3] , [4] , [5] . In turn, DNA damage inhibits cell proliferation and activates cell cycle arrest or leads to apoptosis [6] , [7] . Moreover DOX is the most potent and frequently used chemotherapeutic drug for various malignancies, including cancer of the breast, lung and aggressive lymphomas [8] , [4] .
However, DOX is not only cytotoxic to rapidly proliferating cancer cells but also damages healthy normal tissue and cells to a considerable extent. This is responsible for toxic side effects including myelosuppression, mucositis, stomatitis, alopecia and serious complications such as cardiotoxicity and hepatotoxicity [9] , [10] , [8] . Therefore it is difficult to achieve an adequate chemotherapeutic dosage at the target region through systemic application and the clinical use of the drug is limited. To overcome the problem, there are various approaches attempting to reduce toxicity of DOX while the drug delivery to target tissue and efficacy should be retained or improved at best. One strategy is the use of nanomedicine or nanotherapeutic delivery systems, which provide the possibility to selectively accumulate DOX at target tissue after selective conjugation [11] . Another promising approach is the functionalization of iron oxide magnetic nanoparticles (MNP) with DOX and their utilization in combination with hyperthermia. In general, MNPs release heat during exposure to an alternating magnetic field (AMF) of appropriate amplitude and frequency and this results in so-called magnetic hyperthermia.
In the last years, there are several preclinical approaches indicating an efficient treatment of various cancer cells with DOX-functionalized iron oxide nanoparticles in combination with hyperthermia, including a ovarian carcinoma cell line, a murine melanoma model, in vitro and in vivo therapy of rat glioma or breast cancer cell line [12] , [13] , [14] , [15] . But nevertheless the studies known so far lack a corresponding statement according to the benefits over the conventional therapy [16] . It is very plausible that there are differences in pharmacokinetics between the free anticancer drug DOX, DOX-functionalized MNPs and MNPs alone in vivo as well as in vitro that have to be evaluated. It is still unclear to which extent the presence of DOX really induces an additive effect to hyperthermia from a pathobiological view. Moreover last recent research activities aimed towards enhanced site specificity and internalization of drug carriers in general and of DOX-functionalized MNPs into tumor cells in particular, with the help of multifunctional nanoparticles [17] , [18] . The development currently remains a challenge.
Furthermore it is known that the therapeutic outcome of hyperthermia depends on targetoriented application of thermal stress [19] . Here, the internalization of magnetic nanoparticles into cancer cells bears high potential to improve magnetic hyperthermia therapy [19] . In this context, the multivalent pseudopeptide NuCant (N6L) is of particular interest. The synthetic peptide binds to nucleolin, a nucleoprotein, which is selectively overexpressed on cell surface in various tumor cells [20] , [21] . After binding, cell-surface nucleolin is able to shuttle N6L to the nucleus, where it mediates its lethal effects. N6L exhibits anti-tumor activities by inhibiting tumor growth, and furthermore it is a proapoptodic molecule and inhibits angiogenesis [21] .
Nevertheless, so far it is not known if N6L could potentiate the effect of MNPs functionalized with DOX.
In the present study we search for modalities that can enhance DOX-induced antitumor effects in breast cancer cells and therefore we investigate if: i) the presence of N6L on the surface of 
Discussion
The results presented in this study clearly demonstrate a strengthened antitumor effect of DOX In particular, in water suspension the presence of DOX on MNPs alone did not lower ILP compared to non-functionalized MNPs, but the presence of N6L as well as both ligands DOX and N6L on MNPs distinctly lowered it. This is not due to clustering of MNP since PDI and zeta potential are almost similar. The reason could be an increase in size and corresponds to previously described features in the literature [22] . Nevertheless the bi-functionalized MNPs still showed good heating potential.
The results presented herein showed that the presence of N6L and more prominent the presence of DOX and N6L foster the uptake of MNPs into BT474 cells. Here, the pseudopeptide N6L binds to cell surface proteins nucleolin and nucleophosmin that are overexpressed in most tumor cells [20] , [21] . Another possible mechanism by which N6L strengthened the internalization of MNPs includes the electrostatic interaction with sulfated glucosaminogylcans (GAGs) associated with cell surface [20] , [23] . In this context the negatively charged sulfated GAGs interact with the positively charged N6L and this supports several studies indicating glucoaminoglycan-specific roles in cancer biology [24] [23] . Whereas the binding of N6L to tumor cells is partly due to tumor-specific cell surface target proteins, the uptake mechanism of DOX into the cells is more nonspecific. Basically there are two internalization mechanisms of DOX conjugated MNPs possible: a) DOX is released from MNPs outside the cell in the tumor environment and b) DOX enters the cell due to endocytosis of nanoparticles and is released inside the cell into acidic intracellular vesicles such as endosomes and lysosomes [25] , [26] . In case of the DOX release outside the cell, the drug could interact with cell membranes by insertion into the lipid matrix [27] , [28] , [26] . Within membranes, anionic phospholipids were shown to be important targets for the hydrophobic agent [29] . Moreover passive diffusion is another mechanism of free DOX to enter the cell [29] .
This mechanism is not specific and selective for cancer cells and presents a major disadvantage of conventional mode of DOX delivery. In case of the MNPs conjugated with both DOX and N6L, the internalization effects of each compound very likely to be additive resulting in the best cellular uptake. In turn, the increased uptake of the MNPs functionalized with DOX and N6L is beneficial for therapeutic effects.
Moreover, we clearly demonstrate a reduced viability of target BT474 cells caused by DOX conjugated MNPs and this is potentiated when combined with magnetic hyperthermia and and N6L in a time-dependent manner in vitro. The increased uptake of MNPs conjugated with both DOX and N6L, as we discussed above, causes a higher presence of DOX within the tumor cell, likely accompanied by enhanced mechanism of actions, including oxidative damage and DNA double-strand breaks. Moreover the internalized MNPs into the tumor cells possibly contribute to the decreased cellular growth, too. The internalization of these MNPs through endocytosis and afterwards the exposure to an magnetic field generates intracellular heating spots resulting in an immediate destruction of cells [19] , [30] , [31] , [22] . The effect was also seen via morphological changes of the cells. In absence of a magnetic field, the functionalized MNPs influence the viability of BT474 cells to a lesser extent. Based on these results we conclude that the reduced viability of BT474 cells is due to the combination of heating and the anticancer drug DOX. Both effects potentiate the cytotoxic effects on BT474 cancer cells.
The remarkable reduction of viability of BT474 cells after magnetic hyperthermia combined with MNPs conjugated with DOX alone and both DOX and N6L was not due to activation of p53, caspase-3 or PARP-1 in vitro, as we could demonstrated by Western Blot. Since all of the mentioned proteins play important roles in apoptotic pathways, mechanisms other than apoptosis lead to reduced cell viability [32] , [33] , [34] , [35, 36] . Besides apoptosis there are several other mechanisms leading to programmed cell death, including autophagic cell death, paraptosis, pyroptosis, oncosis, programmed necrosis and caspase-independent cell death [35] , [34] . Additionally, it is well conceivable that DOX is also acting due to such a autophagic pathway as shown for resveratrol, a type of polyphenol antioxidant that is found in various plants and fruits [37] . Interestingly, the free DOX (unbound form) activates apoptotic proteins in BT474 cells. But the effect on viability is less pronounced. One can conclude that observed overexpression of p53, PARP-1 and caspase 3 is associated rather with cell survival than with apoptosis. There is evidence for contribution of the mentioned proteins in cellular survival [38] , [39] , [40] .
Remarkably, the exposure of BT474 cells to DOX functionalized MNPs and hyperthermia indicated a distinct increase of polo-like kinase-1 (Plk-1) in contrast to the free agent or DOX coupled MNPs. Plk-1 belongs to the serine-threonine kinases and plays a critical role during mitotic progression and is involved in DNA damage checkpoint pathways [41] , [42] . The level of Plk-1 expression fluctuates during cell cycle progression. The expression begins to increase in the S-phase and peaks at G2/M transition [41] . An overexpression of Plk-1 arrests BT474 cells in this phase might be well due to cellular repair processes. The repair process can be induced primary due to the treatment of cells with DOX and hyperthermia or as a secondary reaction to the treatment and selection of resistant cells. Moreover our data indicated that DOX conjugated MNPs combined with hyperthermia activated cyclin B1 most pronounced at later time points, in contrast to the free DOX, influencing cyclin B1 expression at rather time points.
With regard of the effect of free agent DOX in the present study, a similar effect was shown for Adriamycin, an anthracycline antibiotic, in HeLa cells. A subcytotoxic concentration of Adriamycin transiently increased the expression level of cyclin B1 and afterwards decreased it, whereas the treatment with cytotoxic concentrations did not influence cyclin B1 expression [43] . Assuming a subcytotoxic field exists for DOX, it is conceivable that the used concentration of DOX in this study is within such a field and thus similar effects as for Adriamycin were caused in the cells. Furthermore it is known, that cyclin B1 is crucial for G2/M progression of the cell cycle [44] . Previous work figured out that treatment with DOX or topoisomerase inhibitors induced cyclin B1 accumulation, leading to G2/M phase arrest in a murine monocytic cell line and Jurkat cells [45] , [46] . Moreover a substance similar to daunorubicin arrested Jurkat cells in the G2/M phase and induced DNA repair rather than cell death [47] . In accordance with the results of other working groups we conclude that the induction of cyclin B1 by DOX and DOX functionalized MNPs in the BT474 cells is related to induction of DNA repair responses rather than apoptosis. Indeed, the additional presence of N6L on DOX conjugated MNPs combined with hyperthermia increased the uptake into the BT474 cells but seems not to further influence mechanisms investigated here.
Our in vivo experiments indicated a prominent reduction of tumor volumes particularly after treatment with DOX functionalized MNPs and hyperthermia. These effects were most pronounced between day 6 and 17 days after treatment. The effect of DOX and hyperthermia seemed to be additive during this time period. The additive effects combined metabolic effects of DOX, such as intercalation with DNA and causing DNA double-strand breaks, and of hyperthermia, including DNA stability, protein conformation and/or expression as well as production of reactive oxygen species [19] , [1] , [48] , [49] . The results show that more than one therapy sessions (including the intratumoral application of MNP) might be necessary in order to achieve long-lasting anti-tumor effects on the tumor volume. One important reason is that due to irregularities in the intratumoral MNP distribution, at least in the used tumor model, in some cases regions of temperature underdosage might occur.
The in vivo effects of DOX conjugated MNPs combined with hyperthermia on protein expression were different from effects of mice treated with magnetic hyperthermia alone, even a comparable reduction of tumor volumes was identifiable. Whereas magnetic hyperthermia alone activated pro-apoptotic proteins, including p53, caspase 3 and PARP, the additional presence of DOX simply induces the expression of p53. We can conclude that the presence of DOX on the MNPs combined with hyperthermia changes the mechanism of action. But these mechanisms have to be studied in detail in the future. Moreover effects on expression of cell cycle proteins CHK2, cyclin B1 and Plk1 were comparable for DOX conjugated MNPs combined with hyperthermia in vivo and in vitro. In contrast DOX coupled MNPs combined with hyperthermia induced the expression of p53 in vivo, but not in vitro.
To sum up, the intratumoral application of DOX coupled MNPs might overcome biological barriers to chemotherapeutic drugs to penetrate into the target cells. In combination with hyperthermia these MNPs can be an effective method in enhancing the localised delivery and penetration of Doxorubicin into breast cancer cells.
Synthesis of magnetic nanoparticles (MNPs). Superparamagnetic iron oxide
nanoparticles (MNPs), named MF66, were synthesized by co-precipitation technique as described previously [22] . They were coated with a dimercaptosuccnic acid (DMSA) and covalently conjugated either with the pseudopeptide Nucant (N6L; MF66-N6L; 4 µmol N6L/ g iron), the chemotherapeutic drug doxorubicin (DOX; MF66-DOX; 40 µmol DOX/ g iron) or both (MF66-N6LDOX; 40 µmol DOX/ g iron; 4µmol N6L/ g iron) as described previously [22] . The amount of immobilized N6L, DOX or both on the MF66-MNPs was quantified as described previously [22] .
Characterization of MF66-MNPs.
The core size of the non-functionalized and functionalized MNPs, the hydrodynamic diameter (expressed as Z-average size) and the Zeta potential (pH 7.4) of the MNPs were determined using Zetasizer equipment (Zetasizer Nano ZS, Malvern Instruments, Germany). To assess the heating potential of the different MF66 formulations the specific absorption rate (SAR) was determined in different environments (ferrofluid, immobilized in 10% polyvinyl alcohol and immobilized in cells 24 h after MNP incubation at 100 µg iron / ml) [50] . In order to compare SAR values with data in the literature the intrinsic loss power (ILP) was calculated as described elsewhere [50] .
Cell culture.
The BT474 cell line, a human breast invasive ductal carcinoma cell line, was selected because of their known sensitivity against magnetic hyperthermia and doxorubicin [51] , [48] . BT474 cells were cultivated at 37°C in a humidified atmosphere containing 5% CO2 and maintained in DMEM with 10% (v/v) fetal bovine serum (FBS) supplemented with glutamax I, sodium pyruvate, glucose (4,5 g/l) (all products from Gibco®, Paisley, Scotland, UK). Cells were passaged after reaching up 90% of confluency. The workflow of the conducted the in vitro experiments with this cell line were shown in the supplements (suppl. figure 1 ).
Determination of cellular uptake of MNP formulations. Quantification of intracellular
iron content 24 h after application of MNP formulations to BT474 cells was determined using flame atomic absorption spectrometry (AAS) as previously described [50] . 
Microscopy.
To investigate the influence of magnetic hyperthermia on morphological changes and detachment of BT474 cells 24 h as well as 48 h after treatment light microscopy (Evos XL imaging system, Thermo Fisher Scientific) was used.
Prussian blue staining for iron detection in cells in vitro.
Internalization and cellular uptake of MNPs (MF66, MF66-DOX 100 µg iron/ml, respectively) and free agent DOX (4 nmol/ml) in BT474 cells was determined as described previously [22] .
Western Blot analysis.
After magnetic hyperthermia treatment, BT474 cells were allowed to grow for additionally 24 h or 48 h in cell culture flasks before they were harvested, washed and lysed with RIPA lysis buffer containing protease inhibitors as described previously [52] .
The following primary mouse antibodies against p53, caspase 3, cyclin B1, Plk-1 were purchased from Santa Cruz biotechnology. Rabbit antibodies against PARP and phospho-CHK2 were obtained from Cell Signaling and mouse anti-actin was obtained from abcam. As secondary goat antibodies against mouse and rabbit IgG HRP were used from Santa Cruz biotechnology according to manufacturer's instructions. Chemoluminescence via horse radish peroxidase substrate was detected using a digital imaging system. Animals were divided into four independent treatment groups: Animals of Group 1 (therapy group) received an intratumoral injection of MF66Dox MNP (0.24 mg iron/100 mm 3 tumor volume; 40 µmol DOX/ g iron) and were exposed to an alternating magnetic field (H = 15.4 kA/ m; f = 435 kHz) for 1 h. Group 2 was used to investigate the impact of non-functionalized MF66 on tumor growth. In this context mice were injected intratumorally with MF66 MNP (0.24 mg iron/100 mm 3 tumor volume) and exposed to an alternating magnetic field at the same conditions as described above. Group 3 monitored the effect of free DOX (Doxorubicinhydrochlorid, cell pharm GmbH, Germany) whereby the animals received intratumorally DOX (9,6 nmol DOX/ 100 mm 3 tumor volume) but no hyperthermia treatment.
Group 4 was used to assess the normal tumor growth in absence of any treatment (intratumoral injection of aqua dest.).
4.11
In vivo effects of magnetic hyperthermia on tumor volume, temperature distribution in tumor tissue, blood count and protein expression. Tumor volume was monitored every three or four days as described elsewhere [52] . The assessment of temperature distribution within tumor area was determined as previously described [50] . Furthermore on day 1, 14 and 28 after the initial treatment, levels of red and white blood cells as well as amount of hemoglobin were determined via hematology (Sysmex pocH-100i, Sysmex GmbH, Germany).
For analysis of protein expression pattern 48 h after treatment, Western blot analysis of excised and homogenized BT474 tumors was performed as described above. Subsequently, the lysates were prepared for Western Blot analysis with the use of the antibodies as mentioned above, except the antibody for caspase3, was purchased from Cell Signaling.
MNP distribution in vivo.
At defined time points after treatment all mice were sacrificed and organs (kidneys, liver, spleen, lungs, heart), muscle tissue and tumors were extracted, dried and incinerated as described elsewhere [22] . Aliquots of each sample were measured using flame atomic absorption spectrometry (AAS). MNPs. AMF alternating magnetic field.
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